An investigational, self-administered, orally dissolving film formulation of dexmedetomidine rapidly relieves agitation in patients with bipolar disorder, new research suggests.
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo .